PL BioScience — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

PL BioScience is an emerging biotech firm focused on revolutionizing cell culture through its proprietary Human Platelet Lysate (HPL) platform, ELAREM™. The company offers a broad portfolio of HPL products designed to replace fetal bovine serum (FBS) in research, diagnostics, and therapeutic cell manufacturing, addressing the growing demand for animal-free, clinically relevant supplements. Its technology supports 2D and 3D cell culture across various safety grades (Research, GMP, GMP-Clinical), positioning it at the intersection of regenerative medicine and advanced in vitro models. PL BioScience aims to bridge the gap between academic research and clinical applications with high-performance, affordable solutions.

Regenerative MedicineMusculoskeletalImmunology

Technology Platform

Patented ELAREM™ platform for manufacturing Human Platelet Lysate (HPL) cell culture supplements. Includes fibrinogen-depleted, virus-inactivated, and hydrogel matrix formulations as xeno-free, animal-component-free alternatives to fetal bovine serum (FBS).

Opportunities

The global shift away from fetal bovine serum (FBS) due to ethical, regulatory, and scientific concerns creates a large and growing market for xeno-free alternatives like HPL.

The rapid expansion of the cell therapy and advanced in vitro model (organoid, organ-on-a-chip) markets provides direct, high-value applications for clinical-grade and research-grade supplements.

Risk Factors

Scalability is constrained by reliance on human platelet donor supply.

The company faces competition from other HPL producers and large life science firms developing defined synthetic media.

Regulatory requirements for clinical-grade materials are stringent and vary by region, posing compliance challenges.

Competitive Landscape

PL BioScience competes in the cell culture supplement market against other specialized HPL manufacturers (e.g., Mill Creek Life Sciences, Macopharma), producers of human serum alternatives, and large conglomerates (e.g., Thermo Fisher Scientific, Merck) offering both serum-based and defined, chemical media. Its differentiation lies in its specialized, patented HPL processing and broad portfolio tailored from research to GMP clinical use.

More companies in Cell & Gene Therapy →More companies in Germany →